Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
Diabetes Metab 101508 Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Gke B (2009) GLP-1 regulates gastroduodenal motility involving cholinergic pathways
Both classes of medications are still considered to be valuable therapies for diabetes management and cardiovascular protection
Although GLP-1 medications are relatively new, several areas of research are generating excitement among lymphatic specialists
